PSMA-Targeted Radiopharmaceuticals for Imaging and Therapy of Prostate Cancer

Abstract Molecular changes in prostate cancer lead to increased expression of prostate-specific membrane antigen (PSMA), which is a suitable target for imaging and therapy using radiopharmaceuticals. Data on the most effective clinically significant PSMA radiopharmaceuticals for the diagnosis and treatment of prostate cancer are summarized. The advantages and disadvantages of ligands based on monoclonal antibodies and their fragments as well as small molecular PSMA inhibitors are discussed.

Авторы
Ivanov S.A. 1 , Kaprin A.D. 1 , Tishchenko V.K. , Petriev V.M. , Vlasova O.P. , Krylov V.V. , Shegai P.V.
Номер выпуска
9
Язык
Английский
Страницы
1608-1612
Статус
Опубликовано
Том
85
Год
2022
Организации
  • 1 Росcийский университет дружбы народов
Ключевые слова
prostate-specific membrane antigen (PSMA); prostate cancer; monoclonal antibodies; small molecule PSMA inhibitors
Дата создания
21.04.2023
Дата изменения
22.07.2024
Постоянная ссылка
https://repository.rudn.ru/ru/records/article/record/93449/
Поделиться

Другие записи